Eflornithine is under clinical development by Orbus Therapeutics and currently in Phase I for Glioblastoma Multiforme (GBM). According to GlobalData, Phase I drugs for Glioblastoma Multiforme (GBM) have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Eflornithine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Eflornithine is under development for the treatment of anaplastic astrocytoma and newly diagnosed glioblastoma. It is a cytostatic small molecule administered orally as a solution. The drug candidate acts by targeting ornithine decarboxylase (ODC). It was also under development for the treatment of grade III malignant gliomas including anaplastic oligodendroglioma, anaplastic oligoastrocytoma and glioblastoma multiforme.
Orbus Therapeutics overview
Orbus Therapeutics is a clinical-stage biopharmaceutical company that develops and commercializes drugs for the treatment of anaplastic astrocytoma, a rare kind of cancer afflicting the central nervous system. It also offers Eflornithine, a cytostatic agent, indicated for the treatment of anaplastic glioma. The company targets the treatment of central nervous system cancer and other rare cancers. Orbus Therapeutics is headquartered in Palo Alto, California, the US.
For a complete picture of Eflornithine’s drug-specific PTSR and LoA scores, buy the report here.